Edesa Biotech
EDSA
21 hedge funds and large institutions have $3.49M invested in Edesa Biotech in 2022 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 1 reducing their positions, and 2 closing their positions.
606% more capital invested
Capital invested by funds: $494K → $3.49M (+$3M)
500% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 1
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
0.69% more ownership
Funds ownership: 0.5% → 1.19% (+0.69%)
0% more funds holding
Funds holding: 21 → 21 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VCIM
Velan Capital Investment Management
Alpharetta,
Georgia
|
+$945K |
| 2 |
LCM
Lynwood Capital Management
Toronto,
Ontario, Canada
|
+$130K |
| 3 |
CM
CM Management
Gulf Breeze,
Florida
|
+$66.8K |
| 4 |
State Street
Boston,
Massachusetts
|
+$21.1K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$16.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$16K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$6.02K |
EDSA Hedge Fund Activity: Q4 2022 in Review
21 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Edesa Biotech (EDSA) for Q4 2022, worth a combined $3.49M — up 606% from $494K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new EDSA positions and 2 closed out — a net gain of 1 holder — while 6 added to existing stakes and 1 trimmed.
The largest buyer was Velan Capital Investment Management, opening a new position worth an estimated $945K. The largest seller was Millennium Management, exiting entirely with an estimated $16K sold.
- 21 institutional investors held Edesa Biotech (EDSA) as of Q4 2022, unchanged from Q3 2022.
- Funds reported $3.49M of Edesa Biotech stock for Q4 2022, up 606% quarter-over-quarter.
- 3 funds opened new Edesa Biotech positions in Q4 2022 and 2 closed out, a net change of +1 holder.
- The largest Edesa Biotech buyer in Q4 2022 was Velan Capital Investment Management, an estimated $945K added.
- The largest Edesa Biotech seller in Q4 2022 was Millennium Management, an estimated $16K sold.
Based on aggregated 13F filings for Q4 2022.